Nicole Bowen
Family · Lees Summit, MONPI 1811471105
Payments from drug & device makers
Across 256 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$960
- Regeneron Healthcare Solutions, Inc.$725
- Sanofi$549
- Jazz Pharmaceuticals Inc.$474
- GSK$409
- Harmony Biosciences LLC$406
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,46898%
- Education$1172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $960 |
| Regeneron Healthcare Solutions, Inc. | 28 | $725 |
| Sanofi | 22 | $549 |
| Jazz Pharmaceuticals Inc. | 18 | $474 |
| GSK | 25 | $409 |
| Harmony Biosciences LLC | 29 | $406 |
| Grifols USA, LLC | 11 | $259 |
| Boehringer Ingelheim | 10 | $205 |
| United Therapeutics Corporation | 7 | $177 |
| Inspire Medical Systems, Inc. | 1 | $143 |
| Verona Pharma, Inc. | 9 | $138 |
| Philips North America LLC | 6 | $121 |
| Genentech USA, Inc. | 6 | $113 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Boston Scientific | 4 | $73 |
| Baxter Healthcare | 3 | $71 |
| Novartis | 4 | $69 |
| Viiv Healthcare Company | 2 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Insmed, Inc. | 3 | $49 |
| AbbVie | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Merck | 2 | $35 |
| Mylan Specialty L.p. | 2 | $32 |
| Amgen | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Baudax Bio Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $23 |
| Acclarent, Inc | 1 | $19 |
| Kaleo, Inc. | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Ossur Americas, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,585 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $108,567 |
| Breo ElliptaFluticasone/Vilanterol | 163 | $85,684 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 102 | $82,185 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 41 | $30,142 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $24,896 |
| Spiriva RespimatTiotropium Bromide | 18 | $11,660 |
| DuleraMometasone/Formoterol | 11 | $7,248 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $5,903 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,947 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $3,143 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $2,706 |
| Zafirlukast | 13 | $2,412 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $2,135 |
| Montelukast Sodium | 102 | $1,081 |
| Ipratropium Bromide | 42 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $409 | $219,147310 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $960 | $87,132121 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $205 | $41,80259 claims |
| MerckDulera | $35 | $7,24811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Lees Summit
- Tamera WolfLees Summit$215K
- Crystal DavisonLees Summit$16K
- Christine HuntLees Summit$12K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.